Business Context and Reporting Period
Company: Trinity Biotech PLC
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: December 17, 2024
Reporting Period: Month of December 2024
Principal Executive Office: IDA Business Park Bray, County Wicklow, Ireland
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a regulatory report regarding a capital raising mechanism.
Material Changes
The filing discloses an amendment to the Company's At the Market Offering Agreement (Sales Agreement) entered into on July 12, 2024, with Craig-Hallum Capital Group LLC. Pursuant to a prospectus supplement filed on December 16, 2024, the Company has the capacity to sell up to an additional $1,000,000 of American Depositary Shares (ADSs).
Guidance, Outlook, and Risks
Capital Raising Activity: The Company may sell ADSs from time to time through Craig-Hallum, acting as sales agent. Each ADS represents 20 of the Company's A Ordinary Shares with a par value of $0.0109 per share.
Legal Opinion: An opinion from Matheson LLP regarding the validity of the ADSs to be sold is included as Exhibit 5.1.
Outlook: No specific operational guidance or management commentary on future performance is provided in this filing.
Investor Verification Checklist
- Verify the total aggregate amount of ADSs previously sold under the Sales Agreement to assess remaining capacity.
- Review the prospectus supplement filed on December 16, 2024, for specific terms of the additional $1,000,000 offering.
- Confirm the current market price of ADSs to evaluate the potential dilution impact of selling up to $1,000,000 worth of shares.
- Check subsequent filings for actual sales executed under this amended agreement.